Genetic Technologies (ASX:GTG) ROE %: 0.00% (As of Jun. 2024)


What is Genetic Technologies ROE %?

Genetic Technologies ASX:GTG ROE % is 0.00% as of Jun. 2024.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Genetic Technologies's annualized net income for the quarter that ended in Jun. 2024 was A$0.00 Mil. Genetic Technologies's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was A$1.83 Mil. Therefore, Genetic Technologies's annualized ROE % for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Genetic Technologies's ROE % or its related term are showing as below:

ASX:GTG's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.22
* Ranked among companies with meaningful ROE % only.

Genetic Technologies  (ASX:GTG) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=0/1.83
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0 / 0)*(0 / 6.187)*(6.187 / 1.83)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*3.3809
=ROA %*Equity Multiplier
=N/A %*3.3809
=0.00 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=0/1.83
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0 / 0) * (0 / 0) * (0 / 0) * (0 / 6.187) * (6.187 / 1.83)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= N/A * N/A * N/A % * 0 * 3.3809
=0.00 %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Genetic Technologies ROE % Related Terms

Genetic Technologies ROE % Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies ROE % Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.87 -39.85 -37.57 -85.17 -184.98

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:GTG vs LDDD, NOTV, ATLN: ROE % Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies ROE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's ROE % falls into.


Genetic Technologies ROE % Calculation

Genetic Technologies's annualized ROE % for the fiscal year that ended in Jun. 2024 is calculated as

ROE %=Net Income (A: Jun. 2024 )/( (Total Stockholders Equity (A: Jun. 2023 )+Total Stockholders Equity (A: Jun. 2024 ))/ count )
=-12.017/( (11.163+1.83)/ 2 )
=-12.017/6.4965
=-184.98 %

Genetic Technologies's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Mar. 2024 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=0/( (0+1.83)/ 1 )
=0/1.83
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Genetic Technologies (ASX:GTG) has a ROE % of 0.00% as of Jun. 2024. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' ROE % too high?
Genetic Technologies' current ROE % is 0.00%.
How does Genetic Technologies' ROE % compare to LDDD and NOTV?
Genetic Technologies' ROE % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current ROE % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.